77 results about "Herpes simplex virus" patented technology

Herpesviridae glycoprotein B (gB) polypeptides comprising a modified ectodomain is stabilized in the prefusion state, enabling development of inhibitors and vaccines directed against these viral pathogens. Modifications to DI, DII, and DV subdomains are important to stabilization of gB in the prefusion state, and additional modifications result in a further improved stabilization of gB in the prefusion state. The gB can be derived from an Epstein Barr Virus (EBV), a Human Cytomegalovirus (CMV), a Human Herpesvirus 6 (HHV6), a Herpes Simplex Virus 1 (HSV1), or a Varicella Zoster Virus (VZV). Polypeptides, nucleic acid constructs, compositions, and methods of using same to elicit an immune response are described.

The invention provides a recombinant herpes simplex virus and a herpes simplex virus modification method. The herpes simplex virus modification method comprises the step of replacing an ICP4 protein coding gene in a herpes simplex virus genome containing an infected cell protein 4 (ICP4) gene with an hTERTp-fluorescent protein expression cassette. The expression cassette comprises an hTERTp promoter and a fluorescent protein coding sequence controlled by the hTERTp promoter, and the transcription direction is opposite to that of an ICP4 promoter in a genome. The hTERTp-fluorescent protein expression cassette in the recombinant virus obtained by the method disclosed by the invention can be normally expressed in response to telomerase activity. Therefore, the recombinant virus is capable of expressing a fluorescent protein, such as mBaoJin, in a cell having human telomerase activity. Cells infected by the virus can be identified through fluorescence signals, and the higher the telomerase activity is, the stronger the fluorescence intensity is. The virus has wide application value in research of tumor action mechanisms and stem cell action mechanisms, health assessment, screening of tumor drugs, research and development of diagnostic reagents and establishment of animal models.

Described herein is an oncolytic herpes simplex virus, G47ΔhIL12A, which is G47Δ containing a cassette expressing a transgene, e.g., human IL-12, driven by a spontaneously arising genetically altered HCMV immediate-early (IE) enhancer / promoter. This virus has augmented (A) production of the transgene and increased virus replication while retaining safety. Also provided are methods of use thereof for treating cancer, e.g., glioblastoma (GBM) and triple-negative breast cancer (TNBC).

The present invention relates to a liquid composition characterized in that it comprises: a live attenuated herpes simplex virus 1 (HSV-1); 17.5 mg / mL to 22.5 mg / mL of recombinant human serum albumin (rHSA); less than 5 mg / mL of sucrose; 26 mg / mL to 32 mg / mL of sorbitol; 13.5 mg / mL to 16 mg / mL of potassium phosphate and 3 mg / mL to 7 mg / mL of sodium chloride, wherein the liquid composition comprises no more than 0.01 mM of any of lactose, gelatin, antibiotic and free amino acids.

The technical problem is to develop a novel armed oncolytic herpes simplex virus (HSV) with G47 delta as a skeleton. Provided is a pharmaceutical composition containing an IL-12 expression-type genetically recombinant herpes simplex virus (HSV) that has a gene encoding a fusion polypeptide in which a 35 kDa light chain (p35) and a 40 kDa heavy chain (p40) of interleukin 12 (IL-12) are linked by two or more elastin motifs, and that has the following characteristics (a) to (c). (a) the ICP6 gene is deleted or inactivated; (b) deletion or inactivation of the gamma34.5 gene; and (c) the alpha 47 gene is deleted or inactivated.

Disclosed is a replication incompetent HSV-1 viral vaccine comprising a modified genome of HSV-1 and at least one antigen. The modification comprises a deletion of internal repeats, an inactivating mutation in ICP47 and an inactivating mutation in the other copy of ICP4. A first antigen of the at least one antigen is driven by a promoter of an immediate early gene, such as ICP4. In a specific example, the HSV-1 viral vaccine expresses antigens from SARS-Cov, SARS-Cov-2 and variants thereof and is used for inducing immune responses against sarbecoviruses in a subject to which the vaccine is administered.

The invention belongs to the field of preparation of high-antibacterial carbon dots, and discloses a high-antibacterial carbon dot, a preparation process and application of the high-antibacterial carbon dot in vaginal gel. The prepared carbon dots are prepared by adopting physical shearing and ultrasonic synergistic pretreatment, then cooperating with microwave gradient energy crushing and stripping, and then performing centrifugation, dialysis purification and vacuum freeze drying, the damage of oxidation or acid treatment to a graphite structure is avoided in the whole process, and the carbon dots have excellent antibacterial and antiviral performance, can effectively inactivate various pathogenic microorganisms, and have good application prospects. Comprise herpes simplex virus, human papilloma virus HPV16, staphylococcus aureus, candida albicans and the like. The invention also optimizes application conditions, is suitable for developing efficient and safe vagina antibacterial gel products, and provides an innovative solution for preventing and treating gynecological infection.

The virus of the present disclosure is a multiple mutant virus in which two or more genes of herpes simplex virus type 2 (HSV-2) are altered and the alteration of the genes is impaired or reduced in gene function.

The present application relates to a virus purification method. The present application relates to a method for purification of herpes simplex virus (HSV-1). The present application also relates to HSV-1 purified according to the method. In particular, the method does not comprise an ultrafiltration concentration step. In particular, the method has a high virus titer yield and a high impurity removal rate.

The invention relates to medicine, and more particularly to therapy, and can be used for treating chronic recurrent infection caused by type 1 and 2 herpes simplex viruses (HSV). According to the proposed method, no sooner than 10-14 days after the subsidence of a repeat flare-up, an extract of aspen bark harvested in the autumn-winter period is administered as an interferon inducer in an amount of 3.7 ml 3 times per day after food and washed down with water at room temperature, the full course of treatment lasting 90 days. The invention provides increased therapeutic efficacy and a reduced frequency and duration of recurrent infection by inducing a high level of (alpha and gamma) interferons in HSV-1 and HSV-2 patients.

The invention discloses application of a gp130 inhibitor in preparation of a medicine for treating virus infection, and relates to the technical field of medicines. Experiments prove that combination of IL-6 family cell factors and a gp130 receptor is inhibited, so that downward signal transmission of a JAK2 / STAT3 signal channel triggered by the IL-6 family cell factors is inhibited, the purposes of inhibiting cell fusion induced by SARS-CoV-2 spike protein and further influencing replication and propagation of SARS-CoV-2 are achieved, and a small-molecule inhibitor SC144 is an inhibitor of gp130, has a remarkable effect of inhibiting SARS-CoV-2 virus replication and has a good application prospect. Meanwhile, the traditional Chinese medicine composition also has a remarkable effect of inhibiting replication of viruses such as human immunodeficiency virus, herpes simplex virus and respiratory syncytial virus.

An HSV vector with ICP27 under control of CXCR4 promoter and ICP34.5 under control of miRNA-124 / 143, wherein the vector has a deletion of one RL and one RS region of the viral genome. Within optional embodiments the mutation is a deletion containing the second copy of the ICP34.5 gene. These constructs provide increased safety without sacrificing efficacy. The HSV vector also incorporates a virus-expressed cytokine cassette encoding IL-12, IL-15 / IL-15RA under the control of CMV promoter.

The present invention provides a herpes simplex virus targeting IL13RA2 that cues an anti-IL13RA2 antibody, or an antigen-binding fragment thereof, to the surface of the virus. Also provided is an anti-IL13RA2 antibody or an antigen-binding fragment thereof that can specifically recognize tumor cells.

Described herein are compositions and methods for reducing or eliminating latent herpes simplex virus type 2 (HSV-2) in HSV-2 infected cells, or for reducing or eliminating latent HSV-2 reactivation in HSV-2 infected cells, thereby providing viable therapeutic methods for latent HSV-2 infection. The compositions comprise a plurality of viral vectors, where the viral vectors comprise a sequence encoding a HSV-2 specific megasuclease. The method comprises delivering a plurality of one or more viral vectors to the HSV-2 infected cell, where each of the one or more viral vectors comprises a sequence encoding an HSV-2 specific megasuclease.

The present invention provides a method for treating spasticity in a subject. The method includes direct administration of a herpes simplex virus 1 (HSV-1) vector harboring a glutamic acid decarboxylase (GAD) gene (preferably. GAD67) into one or more dermatomes of the subject.

The disclosure provides a non-natural herpes simplex virus (“HSV”), compositions comprising, or alternatively consisting essentially of, or yet further consisting of the HSV, and methods of producing the HSV, or infecting a cell with the HSV. Also provided herein are methods of treating cancer or inhibiting the growth or metastasis of cancer cell in a subject in need thereof.

The virus disclosed by the invention is a multi-mutant virus, and the multi-mutant virus is a multi-mutant virus in which more than two genes of herpes simplex virus type 1 (HSV-1) are changed, and the change of the genes is that gene functions are deleted or reduced.

The invention discloses a kit for detecting berberine-resistant viruses and application of the kit. The kit provided by the invention comprises an antibody or an antigen binding fragment thereof, a buffer agent and a signal generation system, the antibody or the antigen binding fragment thereof comprises a heavy chain complementarity determining region HCDR1-3 and a light chain complementarity determining region LCDR1-3, the sequences of the heavy chain complementarity determining region HCDR1-3 are respectively as shown in SEQ ID NO.5-7, the sequences of the light chain complementarity determining region LCDR1-3 are respectively as shown in SEQ ID NO.8-10, and the signal generation system comprises a buffer agent and a signal generation system. Or the sequences of the heavy chain complementarity determining region HCDR1-3 are respectively shown as SEQ ID NO.15-17, and the sequences of the light chain complementarity determining region LCDR1-3 are respectively shown as SEQ ID NO.18-20. The kit can be used for detecting the berberine-resistant herpes simplex virus type 1, so that the treatment effect can be evaluated in advance before berberine is applied for treatment.

The invention relates to the technical field of biological medicines, relates to applications of caerin1.1, caerin1.9 and caerin1.1 / 1.9 in preparation of medicines for preventing / treating viruses, and in particular relates to applications of caerin1.1, caerin1.9 and caerin1.1 / 1.9 in preparation of medicines for preventing / treating herpes simplex viruses. The herpes simplex virus disclosed by the invention is one or two of HSV-1 (Herpes Simplex Virus) or HSV-2 (Herpes Simplex Virus). The caerin1.1, the caerin1.9 or the composition of the caerin1.1 and the caerin1.9 disclosed by the invention has different degrees of prevention and treatment effects on HSV-1 and / or HSV-2, and has a more obvious effect on the HSV-2. Compared with an existing antiviral drug, the compound has a better effect of preventing and treating viruses, the prevention effect is obviously better than that of acyclovir, the application range is wide, and potential toxic and side effects are low.

The invention belongs to the technical field of medicines, and particularly provides a pharmaceutical composition for reducing cytotoxicity and / or resisting herpes simplex virus and application of the pharmaceutical composition.

The application selects highly conservative and excellent interspecies specificity UL49A gene as a target from multiple strains of HSV-1 and related herpes simplex virus (HSV-2, EBV, CMVh and VZV) coding sequences through bioinformatics whole genome alignment, designs and selects specific primer probe combination 124F / 124R / 124P, and establishes a HSV-1 probe method fluorescence quantitative PCR detection system targeting UL49A gene. Based on the primer probe group, the HSV-1 detection kit can be prepared, which is suitable for clinical biological samples such as lesion secretions, aqueous humor and blood, especially can provide a rapid, accurate and high-sensitivity etiological diagnosis scheme for HSV-1 related keratitis, and has good clinical application value.

The application provides a 1-substituted cinnamoyl-2-oxo lycorine compound, a preparation method and application thereof. The structure of the compound is shown in the following formula I: wherein the benzene ring has one or more R groups which are substituents on the benzene ring, and the R group is selected from hydrogen, C 1‑6 alkyl, C 1‑6 alkylalkoxy, halogen, halogenated C 1‑6 alkyl, halogenated C 1‑6 alkoxy, nitro and dioxo. The compound shows excellent antiviral effect, especially for herpes simplex virus type I (HSV-1), and the compound has better safety.

Disclosed are improved Disabled Infectious Single Cycle (DISC) Herpes Simplex Virus (HSV) and their uses in the treatment of cancer or as a vaccine. Also disclosed are improved methods of making DISC HSV.

The present application relates to the field of virology and tumor therapy. In particular, the present application provides a recombinant Herpes Simplex Virus (HSV) which is capable of specifically replicating at high levels in tumor cells and killing tumor cells, but replicating at low levels in normal cells, such that the recombinant Herpes Simplex Virus of the present application not only has a high killing power on tumor cells, but also has significantly reduced side effects (in particular neurotoxicity). Further, the present application relates to a viral vector constructed based on the recombinant Herpes Simplex Virus, a pharmaceutical composition comprising the recombinant Herpes Simplex Virus or the viral vector, and the use of the recombinant Herpes Simplex Virus or the viral vector. The recombinant Herpes Simplex Virus of the present application can be used to infect and kill tumor cells, and can be used to deliver a gene drug into tumor cells for gene therapy.

This invention discloses an antiviral traditional Chinese medicine extract, namely total alkaloids from Sophora flavescens root, which can be used to prepare antiviral drugs. This invention also discloses the application of the antiviral traditional Chinese medicine extract, total alkaloids from Sophora flavescens root, as a viral infection inhibitor and / or in the preparation of drugs for the prevention and / or treatment of viral infectious diseases. It can significantly inhibit the amplification of various viruses, including VSV (vesicular stomatitis virus), EMCV (encephalomyocarditis virus), HSV-1 (herpes simplex virus type I), and H1N1 (influenza A virus), at both the cellular and organismal levels.

The invention relates to a method to measure the level of HSV1-specific antibodies in a biological sample, and methods to stratify herpes simplex encephalitis patients according to their risk of developing autoimmune anti-NMDA-receptor encephalitis. The invention further encompasses pharmaceutical formulations, and methods of treatment useful for treating encephalitis patients.

The invention relates to a herpes simplex virus type 2 (HSV-2) mRNA (messenger Ribonucleic Acid) vaccine as well as a preparation method and application thereof. The mRNA vaccine encodes the variant of the HSV-2 UL37 protein, the protein structure of the variant is more stable, and a nucleotide sequence corresponding to the variant is optimized by a codon, so that the stability and the protein expression level of mRNA are improved. The mRNA further comprises a 5 '-untranslated region, a 3'-untranslated region and a Poly (A) tail, and is delivered through lipid nanoparticles (LNP). The mRNA vaccine disclosed by the invention can induce stronger specific neutralizing antibody and T cell immune response, and has a good application prospect in prevention or treatment of HSV-2 infection.

The invention relates to the technical field of biology, in particular to a freeze-drying type quadruple detection kit for prebiotic four-item limited amplification and application of the freeze-drying type quadruple detection kit. Through optimization of primers, reaction reagents and a reaction system and by means of a hydrogel limiting amplification technology, a limiting amplification reaction system suitable for prebiotic four items, namely toxoplasma gondii, rubella virus, human cytomegalovirus and herpes simplex virus, is developed; the limiting amplification system is used for detecting toxoplasma gondii, rubella virus, human cytomegalovirus and herpes simplex virus, the steps are simple and rapid, the equipment requirement is low, aerosol pollution can be effectively prevented and treated, and the limiting amplification system has high sensitivity and high specificity while having good storage stability.

The invention provides a recombinant herpes simplex virus and a preparation method thereof. The preparation method comprises the step of replacing an original ICP4 coding sequence in a herpes simplex virus genome containing an infected cell protein 4 (ICP4) gene with an hTERTp-ICP4-fluorescent protein expression cassette. The expression cassette comprises an ICP4 coding sequence and a fluorescent protein coding sequence under the control of an hTERTp promoter, and the transcription direction of the expression cassette is opposite to that of an original ICP4 promoter. The recombinant viruses are capable of selectively replicating and indicating telomerase activity in cells having human telomerase activity. Cells infected by the virus can be identified through fluorescence signals, and the higher the telomerase activity is, the stronger the fluorescence intensity is. The virus has wide application value in research of tumor action mechanisms and stem cell action mechanisms, health diagnosis, immune assessment, screening of tumor drugs, research and development of diagnostic reagents and establishment of animal models.

This invention provides a composition for detecting genital tract pathogens, its preparation method, and its application, belonging to the field of nucleic acid or microbial assays or tests. The composition provided by this invention includes a forward primer, a reverse primer, and a probe targeting seven genital tract pathogens. The forward and reverse primers are used to amplify the target DNA. A blocking group is added between the i-th nucleotide and the (i+1)-th nucleotide from the 3' end of the reverse primer, where 4 ≤ i ≤ 8. The probe is labeled with a fluorescent group and a second quenching group at both ends, and a first quenching group in the middle. A portion of the probe's sequence is identical to a portion of the reverse primer's sequence. The composition provided by this invention enables multiplex qualitative detection of seven genital tract pathogens: Neisseria gonorrhoeae, Chlamydia trachomatis, Ureaplasma urealyticum, Ureaplasma microsporum, Mycoplasma hominis, Mycoplasma genitalium, and herpes simplex virus type 2.